Skip to main content
Erschienen in: Virchows Archiv 2/2020

01.08.2020 | Original Article

Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma

verfasst von: Michal Chehover, Reuven Reich, Ben Davidson

Erschienen in: Virchows Archiv | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to analyze the expression and clinical role of Wnt pathway molecules in metastatic high-grade serous carcinoma (HGSC). mRNA expression by qPCR of 20 molecules related to Wnt signaling (WNT1, WNT2, WNT3, WNT4, WNT5A, WNT6, WNT7, WNT11, FZD1, FZD4, FZD5, FZD6, FZD7, FZD8, FZD10, LRP5, LRP6, DKK, CCND, RUNX2) was analyzed in 87 HGSC effusions. Thirty-nine surgical specimens (19 ovarian, 20 from other intra-abdominal sites) were analyzed for comparative purposes. Protein expression of YAP and LRP and their phosphorylated forms by western blotting were analyzed in 52 tumors. Significant differences in mRNA expression as a function of the anatomic site were observed for WNT3 (p = 0.005), WNT5A (p = 0.008), WNT7 (p < 0.001), FRZ5 (p = 0.04), and FRZ6 (p < 0.001). YAP and LRP and their phosphorylated forms were detected in HGSC specimens. FZD10 was overexpressed in effusions from patients who had complete response to chemotherapy compared with those with less favorable response (p = 0.037). WNT4 (p = 0.005), WNT7 (p = 0.047), RUNX2 (p = 0.038), LRP5 (p = 0.022), LRP6 (p = 0.011), FZD6 (p = 0.036), FZD7 (p = 0.004), and FZD10 (p = 0.015) levels were inversely related to primary chemoresistance. High FZD5 levels in pre-chemotherapy effusions tapped at diagnosis and high WNT2 levels in post-chemotherapy disease recurrence effusions were related to shorter overall survival (p = 0.018 and p = 0.011, respectively), whereas high RUNX2 (p = 0.031) and FZD1 (p = 0.029) in post-chemotherapy effusions were associated with longer overall survival. In multivariate analysis of post-chemotherapy cases, WNT2 (p = 0.002), RUNX2 (p = 0.017), FZD1 (p = 0.036), and FZD4 (p = 0.013) were independent prognosticators. In conclusion, expression of Wnt pathway molecules is anatomic site dependent. In HGSC effusions, it is informative of chemoresponse and survival.
Literatur
1.
Zurück zum Zitat Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin 69:280–304PubMed Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin 69:280–304PubMed
2.
Zurück zum Zitat Davidson B (2018) Ovarian carcinoma. In: Davidson B, Firat P, Michael CW (eds) Serous effusions - etiology, diagnosis, prognosis and therapy, 2nd edn. Springer, London Davidson B (2018) Ovarian carcinoma. In: Davidson B, Firat P, Michael CW (eds) Serous effusions - etiology, diagnosis, prognosis and therapy, 2nd edn. Springer, London
3.
Zurück zum Zitat Niehrs C, Acebron SP (2012) Mitotic and mitogenic Wnt signalling. EMBO J 31:2705–2713CrossRef Niehrs C, Acebron SP (2012) Mitotic and mitogenic Wnt signalling. EMBO J 31:2705–2713CrossRef
4.
Zurück zum Zitat Kikuchi A (2003) Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 94:225–229CrossRef Kikuchi A (2003) Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 94:225–229CrossRef
5.
Zurück zum Zitat Wang Y, Nathans J (2007) Tissue/planar cell polarity in vertebrates: new insights and new questions. Development 134:647–658CrossRef Wang Y, Nathans J (2007) Tissue/planar cell polarity in vertebrates: new insights and new questions. Development 134:647–658CrossRef
6.
Zurück zum Zitat Wang Q, Symes AJ, Kane CA et al (2010) A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. PLoS One 5:e10456CrossRef Wang Q, Symes AJ, Kane CA et al (2010) A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. PLoS One 5:e10456CrossRef
7.
Zurück zum Zitat Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG (2019) Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog 58:1770–1782CrossRef Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG (2019) Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog 58:1770–1782CrossRef
8.
Zurück zum Zitat Seagle BL, Dandapani M, Yeh JY, Shahabi S (2016) Wnt signaling and survival of women with high-grade serous ovarian cancer: a brief report. Int J Gynecol Cancer 26:1078–1080CrossRef Seagle BL, Dandapani M, Yeh JY, Shahabi S (2016) Wnt signaling and survival of women with high-grade serous ovarian cancer: a brief report. Int J Gynecol Cancer 26:1078–1080CrossRef
9.
Zurück zum Zitat Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S, DiFeo A (2015) Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget 6:23720–23734CrossRef Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S, DiFeo A (2015) Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget 6:23720–23734CrossRef
10.
Zurück zum Zitat Bodnar L, Stanczak A, Cierniak S et al (2014) Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res 7:16CrossRef Bodnar L, Stanczak A, Cierniak S et al (2014) Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res 7:16CrossRef
11.
Zurück zum Zitat Yoshioka S, King ML, Ran S, Okuda H, Maclean JA 2nd, McAsey M, Sugino N, Brard L, Watabe K, Hayashi K (2012) WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Mol Cancer Res 10:469–482CrossRef Yoshioka S, King ML, Ran S, Okuda H, Maclean JA 2nd, McAsey M, Sugino N, Brard L, Watabe K, Hayashi K (2012) WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Mol Cancer Res 10:469–482CrossRef
12.
Zurück zum Zitat Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, Stronach E, Millan DW, Siddiqui N, Paul J, Brown R (2011) Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 17:4052–4062CrossRef Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, Stronach E, Millan DW, Siddiqui N, Paul J, Brown R (2011) Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 17:4052–4062CrossRef
13.
Zurück zum Zitat Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ (2016) Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget 7:86803–86815CrossRef Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ (2016) Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget 7:86803–86815CrossRef
14.
Zurück zum Zitat Boone JD, Arend RC, Johnston BE, Cooper SJ, Gilchrist SA, Oelschlager DK, Grizzle WE, McGwin G Jr, Gangrade A, Straughn JM Jr, Buchsbaum DJ (2016) Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Lab Investig 96:249–259CrossRef Boone JD, Arend RC, Johnston BE, Cooper SJ, Gilchrist SA, Oelschlager DK, Grizzle WE, McGwin G Jr, Gangrade A, Straughn JM Jr, Buchsbaum DJ (2016) Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Lab Investig 96:249–259CrossRef
15.
Zurück zum Zitat Reinartz S, Finkernagel F, Adhikary T et al (2016) A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol 17:108CrossRef Reinartz S, Finkernagel F, Adhikary T et al (2016) A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol 17:108CrossRef
16.
Zurück zum Zitat Ford CE, Henry C, Llamosas E, Djordjevic A, Hacker N (2016) Wnt signalling in gynaecological cancers: a future target for personalised medicine? Gynecol Oncol 140:345–351CrossRef Ford CE, Henry C, Llamosas E, Djordjevic A, Hacker N (2016) Wnt signalling in gynaecological cancers: a future target for personalised medicine? Gynecol Oncol 140:345–351CrossRef
17.
Zurück zum Zitat Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ (2013) The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol 131:772–779CrossRef Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ (2013) The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol 131:772–779CrossRef
18.
Zurück zum Zitat Teeuwssen M, Fodde R (2019) Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance. J Clin Med 8 Teeuwssen M, Fodde R (2019) Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance. J Clin Med 8
19.
Zurück zum Zitat Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumors of female reproductive organs. IARC, Lyon Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumors of female reproductive organs. IARC, Lyon
20.
Zurück zum Zitat Basu M, Roy SS (2013) Wnt/β-catenin pathway is regulated by PITX2 homeodomain protein and thus contributes to the proliferation of human ovarian adenocarcinoma cell, SKOV-3. J Biol Chem 288:4355–4367CrossRef Basu M, Roy SS (2013) Wnt/β-catenin pathway is regulated by PITX2 homeodomain protein and thus contributes to the proliferation of human ovarian adenocarcinoma cell, SKOV-3. J Biol Chem 288:4355–4367CrossRef
21.
Zurück zum Zitat Lyros O, Rafiee P, Nie L et al (2014) Dickkopf-1, the Wnt antagonist, is induced by acidic pH and mediates epithelial cellular senescence in human reflux esophagitis. Am J Physiol Gastrointest Liver Physiol 306:G557–G474CrossRef Lyros O, Rafiee P, Nie L et al (2014) Dickkopf-1, the Wnt antagonist, is induced by acidic pH and mediates epithelial cellular senescence in human reflux esophagitis. Am J Physiol Gastrointest Liver Physiol 306:G557–G474CrossRef
22.
Zurück zum Zitat Prat J, D'Angelo E, Espinosa I (2018) Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol 80:11–27CrossRef Prat J, D'Angelo E, Espinosa I (2018) Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol 80:11–27CrossRef
23.
Zurück zum Zitat McNeill H, Woodgett JR (2010) When pathways collide: collaboration and connivance among signalling proteins in development. Nat Rev Mol Cell Biol 11:404–413CrossRef McNeill H, Woodgett JR (2010) When pathways collide: collaboration and connivance among signalling proteins in development. Nat Rev Mol Cell Biol 11:404–413CrossRef
24.
Zurück zum Zitat Di Domenico M, Santoro A, Ricciardi C et al (2011) Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer Biol Ther 12:447–457CrossRef Di Domenico M, Santoro A, Ricciardi C et al (2011) Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer Biol Ther 12:447–457CrossRef
Metadaten
Titel
Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma
verfasst von
Michal Chehover
Reuven Reich
Ben Davidson
Publikationsdatum
01.08.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 2/2020
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-019-02737-z

Weitere Artikel der Ausgabe 2/2020

Virchows Archiv 2/2020 Zur Ausgabe

Neu im Fachgebiet Pathologie